CN115025198B - Traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome - Google Patents
Traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome Download PDFInfo
- Publication number
- CN115025198B CN115025198B CN202210742294.XA CN202210742294A CN115025198B CN 115025198 B CN115025198 B CN 115025198B CN 202210742294 A CN202210742294 A CN 202210742294A CN 115025198 B CN115025198 B CN 115025198B
- Authority
- CN
- China
- Prior art keywords
- glossy privet
- privet fruit
- group
- white peony
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
A Chinese medicinal composition and its application in treating perimenopausal syndrome, including fructus Ligustri Lucidi and radix Aconiti lateralis Preparata rhizoma Zingiberis solution, wherein the fructus Ligustri Lucidi and radix Paeoniae alba extract, its preparation method comprises the following steps: step one: preparing glossy privet fruit extract; step two: preparing white peony root extract; step three: preparation of a prescription containing glossy privet fruit and white peony root. The invention adopts the method of combining the glossy privet fruit and the white paeony root to treat the MPS, and the two are compatible, so that the invention not only can tonify kidney yin, but also can calm liver and reduce adverse qi, and comprehensively condition yin and yang of liver and kidney from the pathogenesis root of the MPS. The glossy privet fruit and white peony root compatible prescription can improve the expression of ERalpha and ERbeta in uterus and improve the uterus morphology by increasing the level of E2, beta-EP and NO in rat serum, plays a role in regulating the weight increase condition, uterine atrophy symptom and anxiety emotion of MPS rats, can improve hectic fever symptom at the same time, and has remarkable curative effect.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome.
Background
Perimenopause refers to the period from the onset of ovarian function decline until 1 year after menopause, which is the transition period from vigorous shift in female reproductive function. In this transition period, a series of somatic and psychological symptoms of women, which occur due to unstable hormone levels caused by hypoovariance, are called perimenopausal syndrome (menopausal syndrome, MPS), and the clinical manifestations of MPS are symptoms such as hot flushes, dysphoria, amnesia, irritability, etc. Kidney deficiency is the root of MPS, which is a common symptom, and is mainly characterized by liver-qi excess, mainly manifested by hectic fever, night sweat, dysphoria, hypomenorrhea, etc. According to related data, 84.2% of women can show various symptoms during perimenopause, wherein about 95% and 64% of women can show perimenopause syndrome in the ages of 52-56 years and 42-46 years respectively, serious symptoms such as osteoporosis, cardiovascular diseases, senile dementia and the like, and if the women do not intervene timely, the MPS can form a great threat to the health of the women, and the quality of life of the perimenopause women is seriously reduced.
The existing method for treating the MPS is mainly Hormone Replacement Therapy (HRT), and perimenopausal syndrome is treated by using estrogen, progestogen or estrogen, progestogen and androgen compound medicines, and the method has the advantages of good curative effect, potential danger, adverse reactions such as vaginal bleeding, breast pain and the like, and limited clinical application if the method is used for a long time, the risk of suffering from breast cancer and endometrial cancer is increased.
Disclosure of Invention
The invention provides a traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome, which are used for solving the defects in the prior art.
The invention is realized by the following technical scheme:
a Chinese medicinal composition is characterized in that: comprises a prescription of glossy privet fruit and white peony root and a dried ginger solution of aconite root;
wherein the glossy privet fruit and white peony root compatible prescription comprises glossy privet fruit extract and white peony root extract, and the preparation method comprises the following steps:
step one: preparing glossy privet fruit extract: the extraction method of the glossy privet fruit extract comprises the following steps: extracting crushed fructus Ligustri Lucidi with 8 times of 55-65% ethanol for three times, extracting for 3-4 hr each time, filtering to obtain filtrate, mixing filtrates, and concentrating;
step two: preparation of white peony root extract: the extraction method of the white peony root extract comprises the following steps: extracting crushed radix Paeoniae alba with 8 times of 25-35% ethanol for three times, each time for 3-4 hr, filtering to obtain filtrate, mixing filtrates, and concentrating.
Step three: preparation of a formula of Zhenshao (glossy privet fruit and white peony root): mixing fructus Ligustri Lucidi extract and radix Paeoniae alba extract at a weight ratio of 1-2:1.
The aconite-dried ginger solution comprises 40-60 parts by weight of aconite and 40-60 parts by weight of dried ginger, and the weight ratio of the aconite to the dried ginger is 1-3:1-3.
The preparation method of the aconite dried ginger solution comprises the following steps:
step one: accurately weighing radix aconiti lateralis preparata and dried ginger;
step two: uniformly mixing the aconite and the dried ginger weighed in the first step, adding 180-300 parts by weight of water, soaking for 30-60min, decocting for 40-60min, and filtering to obtain filtrate;
step three: adding 100-150 parts by weight of water into the residues obtained in the step two, decocting for 30-50min, and filtering to obtain filtrate;
step four: mixing the filtrate obtained in the second step and the filtrate obtained in the third step, and heating and concentrating to 80-100 parts by weight.
The content of oleanolic acid in the glossy privet fruit extract and the content of paeoniflorin the white peony root extract are detected by high performance liquid chromatography.
The traditional Chinese medicine composition is an oral preparation.
The application of the traditional Chinese medicine composition in treating perimenopausal syndrome.
The invention has the advantages that: 1. the invention adopts the method of combining the glossy privet fruit and the white paeony root to treat the MPS, and the glossy privet fruit has the effects of nourishing yin, prolonging life and tonifying liver and kidney; the white paeony root has the effects of nourishing blood, regulating menstruation, softening liver, relieving pain, astringing yin, suppressing sweating, and suppressing liver yang, and the two are compatible, so that the white paeony root can tonify kidney yin, suppress liver and reduce adverse qi, comprehensively condition liver and kidney yin and yang from the pathogenesis root of MPS, implement dialectical treatment, has obvious curative effect, has no obvious adverse reaction or side effect, does not have cancerogenic risk, and is suitable for long-term administration. 2. The glossy privet fruit and white peony root compatible prescription can improve the expression of ERalpha and ERbeta in uterus and improve the uterus morphology by increasing the level of E2, beta-EP and NO in rat serum, plays a role in regulating the weight increase condition, uterine atrophy symptom and anxiety emotion of MPS rats, and can improve hectic fever symptom.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions of the prior art, the drawings that are needed in the embodiments or the description of the prior art will be briefly described below, it will be obvious that the drawings in the following description are some embodiments of the present invention, and that other drawings can be obtained according to these drawings without inventive effort to a person skilled in the art.
FIG. 1 is an elevated plus maze experimental score for each group of rats;
FIGS. 2A-C are serum E2, beta-EP, and NO levels in order;
fig. 3A: hypothalamic GnRH content, B: pituitary FSH content, C: pituitary LH content;
fig. 4 is uterine index and endometrium morphology for each group of rats, wherein a: uterus (HE staining. Times.20) of each group of rats, B, C is the index of uterus and the intima thickness of the rats, respectively;
FIG. 5 is the result of immunofluorescent staining of the uterus ERα and ERβ (x 200) of each group of rats, wherein A: erα immunofluorescence results, B: ER beta immunofluorescence staining results;
FIG. 6 shows the results of the expression level of ER mRNA in the uterus of rats in each group, wherein A: ERalpha mRNA expression level, B: expression level of ERbeta mRNA.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1:
a Chinese medicinal composition comprises a formula of radix Paeoniae alba and rhizoma Zingiberis Preparata solution.
Wherein, the prescription of the glossy privet fruit and white paeony root comprises glossy privet fruit extract and white paeony root extract, and the preparation method comprises the following steps:
step one: preparing glossy privet fruit extract: the extraction method of the glossy privet fruit extract comprises the following steps: extracting crushed fructus Ligustri Lucidi with 8 times of 60% ethanol for three times, extracting for 3 hr each time, filtering to obtain filtrate, mixing filtrates, and concentrating. The concentration of oleanolic acid in fructus Ligustri Lucidi extract was 44.54% by high performance liquid chromatography.
Step two: preparation of white peony root extract: the extraction method of the white peony root extract comprises the following steps: extracting crushed radix Paeoniae alba with 8 times of 30% ethanol for three times, extracting for 3 hr each time, filtering to obtain filtrate, mixing filtrates, and concentrating. The concentration of paeoniflorin in the white peony extract is measured to be 50% by high performance liquid chromatography.
Step three: preparation of a formula of Zhenshao (glossy privet fruit and white peony root): mixing the concentrated fructus Ligustri Lucidi extract and radix Paeoniae alba extract at a weight ratio of 1.12:1.
The aconite-dried ginger solution comprises 50 parts by weight of aconite and 50 parts by weight of dried ginger, and the weight ratio of the aconite to the dried ginger is 1:1.
The preparation method of the aconite dried ginger solution comprises the following steps:
step one: accurately weighing 50g of aconite and 50g of dried ginger;
step two: uniformly mixing the aconite and the dried ginger weighed in the first step, adding 180g of water, soaking for 40min, decocting for 50min, and filtering to obtain filtrate;
step three: adding 100g of water into the dregs obtained in the second step, decocting for 30min, and filtering to obtain filtrate;
step four: mixing the filtrate obtained in the second step and the filtrate obtained in the third step, and heating and concentrating to 100g.
1. Experimental materials
1. Animals
Species: SPF-grade SD rat
The source is as follows: beijing vitamin Tonglihua laboratory animal technology Co., ltd (license number SCXK (Beijing) 2016-0006)
Gender: female
Weight of: 180-220g
Feeding conditions: before the formal experiment, the free diet drinking water is adaptively fed for one week, the indoor temperature is controlled at 20-25 ℃, the relative humidity is 40-60%, and 12/12 hours are alternated day and night.
2. A Chinese medicinal composition comprises: zhenshao compatible prescription, aconite root and dried ginger solution, estradiol valerate and Kunbao pill
2. Experimental method
1. Preparation of animal model: the 84 female SD rats were randomly divided into 7 groups according to mass, wherein groups 1 to 6 were subjected to ovariectomy, and group 7 was subjected to Sham surgery, which was Sham surgery group (Sham), and the number of rats in each group was 12. After 7 days of operation, detecting by adopting a vaginal resistance method, and rejecting unqualified rats. 14 days after surgery, rats of groups 1-6 were given a solution of aconite root in Zingiberis rhizoma (dose calculated on body weight: 10ml/kg; dosing frequency: once a day, 7 consecutive days), and rats of group 7 were given an equal amount of equally frequent distilled water. After 21 days, rats in the operation group were again divided into six groups according to the body mass, namely a Model group (Model), a Zhenshao prescription Low dose group (Low ZS), a Middle dose group (Middle ZS), a High dose group (High ZS), an estradiol valerate group (Progynova) and a Kunbao pill group (Kunbao Wan).
The experiment is divided into 7 groups, namely a Sham operation group (Sham), a Model group (Model), a Zhenshao prescription Low-dose group (Low ZS), a Middle-dose group (Middle ZS), a High-dose group (High ZS), an estradiol valerate group (Progynova) and a Kunbao pill group (Kunbao Wan). Wherein the Sham and Model groups (Sham) were daily gavaged with distilled water. The model group adopts castration and heat-filled traditional Chinese medicine (aconite dried ginger) to prepare a rat model, and the traditional Chinese medicine is continuously filled into the stomach for four weeks. The administration methods of each group are shown in table 1.
TABLE 1 methods of administration
| Group of | Experimental protocol | Dosage (mg/kg) | Time |
| False operation group (Sham) | Distilled water | 0 | 4 weeks of |
| Model group (Model) | Distilled water | 0 | 4 weeks of |
| Low dose group (LowZS) | Zhenshao compatible prescription | 100 | 4 weeks of |
| Medium dose group (MiddleZS) | Zhenshao compatible prescription | 200 | 4 weeks of |
| High dose group (HighZS) | Zhenshao compatible prescription | 400 | 4 weeks of |
| Estradiol valerate (Progynova) | Estradiol valerate | 0.1 | 4 weeks of |
| Kunbaowang pill group (Kunbaowan) | Kunbao pill | 1000 | 4 weeks of |
Remarks: the doses in Table 1 are calculated as weight-based doses
2. Study of drug efficacy
The drug effect study mainly comprises the measurement of the weight increase condition of rats, the overhead plus maze score, the E2, beta-EP and NO contents in the serum of each group of rats, the hormone contents in the brain tissues of each group of rats, the uterine index and endomembrane morphology of each group of rats, the alpha and beta immunofluorescence optical density values (IOD values) of the uterine estrogen receptors of each group of rats, the expression of ER mRNA of each group of rats and the like. In this example, the enzyme-linked immunosorbent assay (ELISA) was used to detect E2, NO, beta-EP, gnRH in hypothalamus, FSH and LH levels in pituitary; detecting uterine pathological changes using HE staining; immunofluorescence and fluorescent quantitative PCR methods are used for detecting the expression characteristics of the uterine estrogen receptor.
(1) Rat weight gain measurement
After the start of the experiment, the body weight of the rat was measured weekly, and the increase in body mass (body mass after administration-body mass before administration) was calculated. Four weeks after dosing, rats in the model group had significantly up-regulated body weight (P < 0.01) compared to sham groups; compared with the model group, the weight increase of the high-dose group of the Zhenshao compatible prescription is slow (P is less than 0.05) and the trend of the high-dose group is the same as that of the oestradiol valerate group. (see Table 2)
Table 2 perimenopausal syndrome (MPS) rat weight change profile (x±s, n=10)
| Group of | Preoperative (g) | After molding (g) | Weight gain (g) | After administration (g) | Weight gain (g) |
| False operation group | 234.4±4.1 | 304.7±13.6 | 70.3±15.1 | 321.30±17.6 | 16.6±10.9 |
| Model group | 232.1±6.9 | 348.8±33.8 ## | 116.7±28.4 ## | 376.1±42.3 ## | 27.3±12.7 |
| Kunbao pill group | 234.6±6.1 | 345.7±23.3 | 111.1±22.1 | 378.4±26.7 | 32.8±11.9 |
| Estradiol valerate group | 234.3±11.7 | 348.6±17.0 | 114.3±15.2 | 360.4±21.2 | 11.8±23.0 |
| High dose group | 233.8±10.0 | 342.8±25.8 | 109.0±26.2 | 349.3±42.8 | 6.6±19.6 ** |
| Medium dose group | 235.0±8.5 | 347.1±16.6 | 112.1±16.5 | 364.6±19.9 | 17.5±13.1 |
| Low dose group | 231.1±9.4 | 347.2±16.4 | 116.1±13.3 | 370.8±16.6 | 23.6±11.8 |
Note that: in comparison with the sham-operated group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
(2) overhead plus maze score
As shown in fig. 1, the number of times the model group entered the open arm was reduced compared to the control group, with OE% significantly down-regulated (P < 0.05); compared with the model group, the OE% of the oestradiol valerate group is obviously increased (P < 0.05), the time and the times of entering an open arm of the Zhenshao compatibility formula are increased, and the OE% and the OT% are obviously increased (P < 0.05). Aiming at open arms and closed arms, rats have research and avoidance contradiction behaviors, so anxiety psychology is caused, and at the moment, the values of OE% and OT% are reduced.
Note that: in comparison with the control group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
(3) estradiol (E2), beta-endorphin (beta-EP), nitric Oxide (NO) content in serum of rats of each group
Compared with the control group, the concentration of E2, beta-EP and NO in the serum of the model group is obviously reduced (P <0.05, P < 0.01); compared with the model group, the E2 content of the compatible prescription of estradiol valerate and Zhenshao is obviously increased (P < 0.05), the beta-EP concentration of the high-dose group and the middle-dose group is obviously increased (P < 0.01), and the NO concentration of the Kunbao pill group, the high-dose group and the low-dose group is obviously increased (P < 0.05). (see FIG. 2)
Premature ovarian failure affects beta-EP secretion in perimenopausal rats, beta-EP acts as a neuromediator, on the one hand, its concentration reduction affects hypothalamic stability, which is prone to vasomotor dysfunction, and on the other hand, the hypothalamic thermoregulation centre has endorphin sensitivity, and central beta-EP reduction after menopause, and hot flashes are manifested through thermoregulation pathways. Furthermore, nitric Oxide (NO) is the major vasomotor factor, and therefore the occurrence of hot flashes is associated with abnormal levels of both NO and beta-EP. The experiment shows that after the prescription is used, the beta-EP concentration of the glossy privet fruit and white peony root compatible prescription is obviously up-regulated in the high-dose group and the medium-dose group, and the NO concentration of the high-dose group is obviously up-regulated, so that the glossy privet fruit and white peony root compatible prescription can improve the hectic fever symptom.
Note that: in comparison with the control group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
(4) hormone content in brain tissue of rats of each group
Female rats' reproductive endocrine function is mainly regulated by hypothalamic-pituitary-ovarian axis (HPGA), perimenopausal rat HPGA disorders, resulting in abnormal GnRH secretion, thus causing endocrine dyscrasia, premature ovarian failure, fluctuation of sex hormone levels, and decline of estrogen content in the body, followed by a series of clinical symptoms.
As shown in fig. 3, compared with the control group, the gonadotropin releasing hormone (GnRH), follicle Stimulating Hormone (FSH), luteinizing Hormone (LH) contents in the brain tissues of the model group were all significantly up-regulated (P < 0.05); compared with a model group, the concentration of GnRH in a high-dose group and a low-dose group of the Zhenshao prescription is obviously reduced (P < 0.05), the trend of the GnRH is consistent with that of Kunbao pills and estradiol valerate groups, the concentration of FSH in the estradiol valerate groups is obviously reduced (P < 0.05), the concentration of FSH in the low-dose group of the Zhenshao prescription is reduced but has no statistical significance, and the LH content is obviously reduced (P <0.05 and P < 0.01) in a dosing group. Experimental results show that after treatment by the glossy privet fruit and white peony root compatible prescription, the administration group approaches to the shao operation group at three hormone levels. This suggests that the Zhenshao compatible prescription has estrogen-like effect and exerts therapeutic effect by balancing HPGA.
Note that: in comparison with the sham-operated group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
(5) uterine index and intima morphology of each group of rats
Compared with the control group, the endometrium of the model group is thinned (P < 0.01), the uterus is obviously atrophic, and the uterus index is obviously down-regulated (P < 0.01); compared with the model group, the uterus index of the high-dose group of the compatibility formula of the estradiol valerate group and the Zhenshao is obviously up-regulated (P is less than 0.05), and the thickness of the endometrium layer is not obviously changed. (see FIG. 4)
Perimenopausal rats often suffer from uterine atrophy and thin endometrium. If estrogen is used alone without progesterone during the course of treatment, the likelihood of endometrial cancer is increased. Thus, the treatment should improve uterine atrophy without inducing endometrial hyperplasia. Compared with the model group, the Zhenshao compatible prescription has the advantages that the uterine index of each group is increased, uterine atrophy is improved, and the side effect of single use of estrogen is reduced.
Note that: in comparison with the sham-operated group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
(6) alpha and beta immunofluorescence optical density values (IOD values) for the uterine estrogen receptors of each group of rats
Compared to the sham surgery group, the IOD values for both estrogen receptors α and β were significantly reduced (P < 0.01) in the model group; compared with the model group, the IOD value of estrogen receptor alpha in the high and medium dose groups of Zhenshao prescription is obviously increased (P < 0.01) and is consistent with the trend of oestradiol valerate group, and the IOD value of estrogen receptor beta in each group of Zhenshao prescription is obviously increased (P < 0.05). (see FIG. 5)
Note that: in comparison with the control group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
(7) ER mRNA expression in the uterus of rats of each group
Compared with the control group, the ER mRNA of the model group has a tendency to be reduced, the ER alpha mRNA is obviously down-regulated (P < 0.01), and the ER beta mRNA is down-regulated without statistical difference (P > 0.05); compared with the model group, the ERalpha mRNA of the high-dose group of the Zhenshao compatible prescription is obviously up-regulated (P < 0.05), the expression of the ERalpha mRNA is consistent with that of the oestradiol valerate group, and the ERbeta mRNA of each group of the Zhenshao compatible prescription has up-regulation trend, but no statistical difference (P > 0.05) is formed. (see FIG. 6)
Note that: in comparison with the control group, # P＜0.05， ## p is less than 0.01; in comparison with the set of models, * P＜0.05， ** P＜0.01。
the rats in the model group had significantly higher body weight gain (P < 0.01) than the sham group; elevated plus maze test found a significant reduction in OE% (P < 0.05); the content of E2, beta-EP and NO in serum is obviously reduced; hypothalamic GnRH, pituitary FSH and LH levels were significantly increased (P < 0.05); HE pathology detection shows that uterus is obviously atrophic, uterine index is obviously reduced (P < 0.01), endometrium is thinned (P < 0.01), and immunofluorescence detection shows that ERalpha and ERbeta expression is obviously reduced. Compared with the model group, after treatment by the glossy privet fruit and white peony root compatible prescription, the anxiety-like behavior of the rat is improved and the weight growth is controlled as can be seen from the overhead maze test and the weight growth condition of the rat; the uterine index and endometrium form of the rat and the alpha and beta immunofluorescence optical density values of the uterine estrogen receptor can be seen, the uterine index of the rat is up-regulated, the uterine atrophy condition is improved, the content of E2, beta-EP and NO is increased, the content of FSH, LH, gnRH is reduced, and the abnormal performance of the glossy privet fruit and white peony root compatible prescription can be better improved.
The Zhenshao compatible prescription has obvious curative effects on main symptoms of MPS, anxiety, irritability and the like by increasing the E2, beta-EP and NO levels in serum of a model rat, improving the expression of ER alpha and ER beta in uterus, improving the uterine morphology, playing a role in regulating the weight growth condition, uterine atrophy symptoms and anxiety emotion of the MPS rat.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (5)
1. A traditional Chinese medicine composition for treating perimenopausal syndrome is characterized in that: the traditional Chinese medicine composition consists of a glossy privet fruit and white peony root compatible prescription and a aconite root and dried ginger solution;
the glossy privet fruit and white peony root compatible prescription consists of glossy privet fruit extract and white peony root extract, and the preparation method comprises the following steps:
step one: preparing glossy privet fruit extract: the extraction method of the glossy privet fruit extract comprises the following steps: extracting crushed fructus Ligustri Lucidi with 8 times of 55-65% ethanol for three times, extracting for 3-4 hr each time, filtering to obtain filtrate, mixing filtrates, and concentrating;
step two: preparation of white peony root extract: the extraction method of the white peony root extract comprises the following steps: extracting crushed radix Paeoniae alba with 8 times of 25-35% ethanol for three times, extracting for 3-4 hr each time, filtering to obtain filtrate, mixing filtrates, and concentrating;
step three: preparation of a formula of Zhenshao (glossy privet fruit and white peony root): uniformly mixing the glossy privet fruit extract and the white paeony root extract according to the weight ratio of 1-2:1;
the aconite-dried ginger solution is prepared by decocting and concentrating 40-60 parts by weight of aconite and 40-60 parts by weight of dried ginger, wherein the weight ratio of the aconite to the dried ginger is 1-3:1-3.
2. The traditional Chinese medicine composition for treating perimenopausal syndrome according to claim 1, wherein: the preparation method of the aconite dried ginger solution comprises the following steps:
step one: accurately weighing radix aconiti lateralis preparata and dried ginger;
step two: uniformly mixing the aconite and the dried ginger weighed in the first step, adding 180-300 parts by weight of water, soaking for 30-60min, decocting for 40-60min, and filtering to obtain filtrate;
step three: adding 100-150 parts by weight of water into the residues obtained in the step two, decocting for 30-50min, and filtering to obtain filtrate;
step four: mixing the filtrate obtained in the second step and the filtrate obtained in the third step, and heating and concentrating to 80-100 parts by weight.
3. The traditional Chinese medicine composition for treating perimenopausal syndrome according to claim 1, wherein: the content of oleanolic acid in the glossy privet fruit extract and the content of paeoniflorin the white peony root extract are detected by high performance liquid chromatography.
4. The traditional Chinese medicine composition for treating perimenopausal syndrome according to claim 1, wherein: the traditional Chinese medicine composition is an oral preparation.
5. Use of a pharmaceutical composition according to claim 1 for the preparation of a product for the treatment of perimenopausal syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210742294.XA CN115025198B (en) | 2022-06-28 | 2022-06-28 | Traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210742294.XA CN115025198B (en) | 2022-06-28 | 2022-06-28 | Traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115025198A CN115025198A (en) | 2022-09-09 |
| CN115025198B true CN115025198B (en) | 2023-07-25 |
Family
ID=83127285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210742294.XA Active CN115025198B (en) | 2022-06-28 | 2022-06-28 | Traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115025198B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110575495A (en) * | 2019-09-29 | 2019-12-17 | 甘肃中医药大学 | traditional Chinese medicine compound preparation for preventing and treating perimenopausal syndrome and preparation method thereof |
-
2022
- 2022-06-28 CN CN202210742294.XA patent/CN115025198B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115025198A (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | A combination of Semen Cuscutae and Fructus Lycii improves testicular cell proliferation and inhibits their apoptosis in rats with spermatogenic dysfunction by regulating the SCF/c-kit--PI3K--Bcl-2 pathway | |
| Khanage et al. | Herbal drugs for the treatment of polycystic ovary syndrome (PCOS) and its complications | |
| WO2019154161A1 (en) | Pharmaceutical composition for treating male diseases, and preparation method therefor and use thereof | |
| WO2022227814A1 (en) | Traditional chinese medicine composition for treating infertility, preparation method therefor, and application thereof | |
| Li et al. | Protective effect of Clinopodium chinense (Benth.) O. Kuntze against abnormal uterine bleeding in female rats | |
| WO2021253742A1 (en) | Application of wubi chinese yam pills in preparation of drug for treatment of premature ovarian insufficiency | |
| Wang et al. | Research progress on the effect of traditional Chinese medicine on signal pathway related to premature ovarian insufficiency | |
| Hossein-Rashidi et al. | Effects of Vitex agnus-castus extract on the secretory function of pituitary-gonadal axis and pregnancy rate in patients with premature ovarian aging (POA) | |
| CN115025198B (en) | Traditional Chinese medicine composition and application thereof in treating perimenopausal syndrome | |
| US8383165B1 (en) | Composition and method for fertility therapy using nutritional supplements | |
| KR102348874B1 (en) | Composition for preventing or Treating female climacteric syndrome comprising Polygonatum extracts | |
| Prabhu et al. | Medicinal plants and polycystic ovary syndrome | |
| Azeemuddin et al. | Effect of “DXB-2030,” a polyherbal formulation, on experimental polycystic ovary syndrome associated with hyperandrogenism | |
| Navaei et al. | The Effect of plantago major VAGINAL SUPP on Heavy Menstrual Bleeding Patients with Uterine Leiomyoma: A Double-blind Randomized Clinical Trial | |
| Negahdari et al. | A comparison between the effect of trans-anethole and metformin on biochemical parameters of polycystic ovary syndrome in rats | |
| CN103479859B (en) | Traditional Chinese medicine composition for treating hyperandrogenism of polycystic ovary syndrome | |
| CN113144068A (en) | Traditional Chinese medicine composition for treating kidney deficiency type hypomenorrhea and application thereof | |
| CN102247505A (en) | Chinese medical composition for treating sterility of multiparous cow after repeated mating and treatment method of sterility of multiparous cow after repeated mating | |
| CN105920221A (en) | Pharmaceutical composition for treating anovulatory infertility and its preparation method and use | |
| Ross | Efficacy of a standardized isopropanolic black cohosh (Actaea racemosa) extract in treatment of uterine fibroids in comparison with tibolone among patients with menopausal symptoms | |
| Ahmadi et al. | Saffron and childbirth; a triple blind clinical trial | |
| CN116236526B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| CN115068578B (en) | Traditional Chinese medicine composition for treating insulin resistance type polycystic ovary syndrome and application thereof | |
| CN117442659B (en) | Kidney-tonifying spleen-regulating liver-soothing composition and preparation method and application thereof | |
| Kumar et al. | Therapeutic Effect of Herbal Medicinal Plants on Polycystic Ovarian Syndrome: A Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |